181 related articles for article (PubMed ID: 14565594)
21. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
22. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
23. Ultrasound analyses of the calcaneus predict relative risk of the presence of at least one vertebral fracture and reflect different physical qualities of bone in different regions of the skeleton.
Pfeifer M; Pollaehne W; Minne HW
Horm Metab Res; 1997 Feb; 29(2):76-9. PubMed ID: 9105904
[TBL] [Abstract][Full Text] [Related]
24. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
25. Ultrasound velocity and attenuation at different skeletal sites compared with bone mineral density measured using dual energy X-ray absorptiometry.
Cunningham JL; Fordham JN; Hewitt TA; Speed CA
Br J Radiol; 1996 Jan; 69(817):25-32. PubMed ID: 8785618
[TBL] [Abstract][Full Text] [Related]
26. The relationship between bone mineral density and ultrasound in postmenopausal and osteoporotic women.
Yeap SS; Pearson D; Cawte SA; Hosking DJ
Osteoporos Int; 1998; 8(2):141-6. PubMed ID: 9666937
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
28. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
29. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
30. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
31. Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
Shimon I; Eshed V; Doolman R; Sela BA; Karasik A; Vered I
Osteoporos Int; 2005 Dec; 16(12):1591-6. PubMed ID: 16362147
[TBL] [Abstract][Full Text] [Related]
32. Alendronate for the Treatment of Osteoporosis in Men: A Meta-Analysis of Randomized Controlled Trials.
Xu Z
Am J Ther; 2017; 24(2):e130-e138. PubMed ID: 27058577
[TBL] [Abstract][Full Text] [Related]
33. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
34. Effects of alendronate on bone density in men with primary and secondary osteoporosis.
Ho YV; Frauman AG; Thomson W; Seeman E
Osteoporos Int; 2000; 11(2):98-101. PubMed ID: 10793867
[TBL] [Abstract][Full Text] [Related]
35. Comparison of speed of sound and ultrasound attenuation in the os calcis to bone density of the radius, femur and lumbar spine.
Rossman P; Zagzebski J; Mesina C; Sorenson J; Mazess R
Clin Phys Physiol Meas; 1989 Nov; 10(4):353-60. PubMed ID: 2698780
[TBL] [Abstract][Full Text] [Related]
36. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of primary hyperparathyroidism on ultrasound properties of bone.
Ingle BM; Thomas WE; Eastell R
Osteoporos Int; 2002 Jul; 13(7):572-8. PubMed ID: 12111018
[TBL] [Abstract][Full Text] [Related]
38. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis.
Ringe JD; Dorst A; Farahmand P
Arzneimittelforschung; 2010; 60(5):267-72. PubMed ID: 20533764
[TBL] [Abstract][Full Text] [Related]
40. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
